The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.
Massachusetts General Hospital’s Severe Immunotherapy Complications Service focuses on the increasing number of “rare” cases of immunotherapy-related adverse events.
Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor.
New trial results examine whether there's a drug superior to sorafenib when it comes to treating kidney cancer.
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases.
Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology.
The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib.
In this randomized phase III trial, researchers compared cytoreductive nephrectomy vs sunitinib alone in patients with metastatic renal cell carcinoma.
The KEYNOTE-426 study evaluated pembrolizumab plus axitinib vs sunitinib in patients with metastatic RCC with intermediate/poor risk disease and those with sarcomatoid features.
The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval.